Howard W. Robin Sells 83,334 Shares of Nektar Therapeutics (NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 83,334 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $23.57, for a total value of $1,964,182.38. Following the sale, the chief executive officer now owns 235,838 shares in the company, valued at approximately $5,558,701.66. The sale was disclosed in a filing with the SEC, which is available through this link.

Nektar Therapeutics (NASDAQ NKTR) opened at $23.75 on Friday. The company has a quick ratio of 3.82, a current ratio of 3.97 and a debt-to-equity ratio of 72.60.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.04). Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The company had revenue of $34.60 million during the quarter, compared to the consensus estimate of $33.64 million. During the same quarter in the prior year, the business earned ($0.36) EPS. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. sell-side analysts forecast that Nektar Therapeutics will post -0.95 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Howard W. Robin Sells 83,334 Shares of Nektar Therapeutics (NKTR) Stock” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/11/05/howard-w-robin-sells-83334-shares-of-nektar-therapeutics-nktr-stock.html.

Several hedge funds have recently bought and sold shares of the company. Louisiana State Employees Retirement System lifted its holdings in shares of Nektar Therapeutics by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock valued at $1,236,000 after purchasing an additional 500 shares in the last quarter. LS Investment Advisors LLC lifted its holdings in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 535 shares in the last quarter. World Asset Management Inc lifted its holdings in shares of Nektar Therapeutics by 5.6% in the second quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock valued at $199,000 after purchasing an additional 539 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 692 shares in the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of Nektar Therapeutics by 1.0% in the second quarter. Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company’s stock valued at $1,582,000 after purchasing an additional 800 shares in the last quarter. Institutional investors own 95.13% of the company’s stock.

Several brokerages have issued reports on NKTR. Jefferies Group LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Nektar Therapeutics in a report on Friday, August 18th. BidaskClub upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. HC Wainwright began coverage on Nektar Therapeutics in a report on Monday, August 7th. They issued a “buy” rating and a $31.00 price target on the stock. Zacks Investment Research lowered Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Finally, William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $26.80.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

What are top analysts saying about Nektar Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nektar Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit